Brief: Biocartis Announces First U.S. FDA Oncology Assay Submission
20/04/2021 06:09
April 20 (Reuters) - Biocartis Group NV BCART.BR :
* BIOCARTIS ANNOUNCES US FDA 510(K) SUBMISSION OF ITS IDYLLA
MSI
TEST
* FIRST US FDA ONCOLOGY ASSAY SUBMISSION FOR BIOCARTIS
Source text for Eikon: ID:nNDLb99nJy
Further company coverage: BCART.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Biocartis NV
See all newsBrief: Biocartis Group NV Appoints Randy Polonsky As Chief Financial Officer
Brief: Biocartis Appoints New Chief Business Officer, VP Global Marketing
Brief: Biocartis And Merck To Collaborate
Brief: Biocartis's Secured Creditors Enforced Their Security Over Subsidiaries Shares
Brief: Biocartis Announces Expansion Of Its Collaboration With Apis Assay Technologies